Xeris Pharmaceuticals, Inc. (XERS): Price and Financial Metrics
XERS Price/Volume Stats
Current price | $1.78 | 52-week high | $3.26 |
Prev. close | $1.78 | 52-week low | $1.46 |
Day low | $1.78 | Volume | 1,345,157 |
Day high | $1.90 | Avg. volume | 2,164,947 |
50-day MA | $2.39 | Dividend yield | N/A |
200-day MA | $2.21 | Market Cap | 250.01M |
XERS Stock Price Chart Interactive Chart >
Xeris Pharmaceuticals, Inc. (XERS) Company Bio
Xeris Pharmaceuticals, Inc., a specialty pharmaceutical company, develops and commercializes ready-to-use injectable and infusible drug formulations. Its proprietary XeriSol and XeriJect formulation technologies allow for the subcutaneous and intramuscular delivery of highly-concentrated, ready-to-use formulations of peptides, proteins, antibodies, and small molecules using commercially available syringes, auto-injectors, multi-dose pens, and infusion pumps. The company’s lead product candidate is glucagon rescue pen, which has completed Phase III clinical trials for the treatment of severe hypoglycemia, a potentially life-threatening condition in people with diabetes. Its product candidates also comprise self-administered glucagon that is in Phase IIa clinical trials for the treatment of post-bariatric hypoglycemia; continuous glucagon, which is in Phase II clinical trials for the treatment of congenital hyperinsulinism; continuous glucagon that is in Phase IIa clinical trials for the treatment of hypoglycemia-associated autonomic failure; self-administered glucagon, which is in Phase IIa clinical trials for the treatment of exercise-induced hypoglycemia; and ready-to-use glucagon that is in Phase II clinical trials for use in a bi-hormonal artificial pancreas closed-loop systems. The company’s preclinical programs include ready-to-use diazepam, a ready-to-use diazepam formulation for the treatment of ARS in patients with epilepsy; and pram-insulin, a ready-to-use fixed dose combination of insulin and pramlintide. It serves patients, caregivers, and health practitioners. The company was founded in 2005 and is based in Chicago, Illinois.
Latest XERS News From Around the Web
Below are the latest news stories about XERIS BIOPHARMA HOLDINGS INC that investors may wish to consider to help them evaluate XERS as an investment opportunity.
Xeris Biopharma to Present at the 42nd Annual J.P. Morgan Healthcare ConferenceCHICAGO, December 27, 2023--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patients’ lives by developing and commercializing innovative products across a range of therapies, today announced that Paul R. Edick, Xeris’ Chairman and CEO, will present an overview of the Company at the 42nd Annual J.P. Morgan Healthcare Conference on Thursday, January 11, 2024 at 12:00 pm Pacific Time. To access the presentation, please visit "Events" |
11 High Growth Micro-Cap Stocks to BuyIn this article, we discuss 11 high-growth micro-cap stocks to buy. To skip the detailed analysis and past performance of micro-cap stocks, go directly to the 5 High Growth Micro-cap Stocks to Buy. Shares of small companies with market capitalization usually between $50 to $300 million are considered micro-cap stocks. The risk in these investments […] |
My Top Small-Cap Stock Pick for 2024 Is a Biotech With a Big OpportunityIt is that time of year when market strategists and pundits roll out their predictions and stock picks for the year ahead. This may be done to extend patent life or to produce a more convenient way to deliver the drug. |
President & COO of Xeris Biopharma Holdings Picks Up 7.5% More StockEven if it's not a huge purchase, we think it was good to see that John Shannon, the President & COO of Xeris Biopharma... |
Xeris Biopharma CEO unveils game-changing drug innovations and record financial successXeris Biopharma CEO Paul Edick joined Steve Darling from Proactive to share insights on the company's focus on innovative drug formulation technology after reporting strong third-quarter results. |
XERS Price Returns
1-mo | -15.24% |
3-mo | -24.58% |
6-mo | 7.23% |
1-year | -22.27% |
3-year | -55.50% |
5-year | -81.32% |
YTD | -24.26% |
2023 | 76.69% |
2022 | -54.61% |
2021 | -40.45% |
2020 | -30.21% |
2019 | -58.53% |
Continue Researching XERS
Want to see what other sources are saying about Xeris Pharmaceuticals Inc's financials and stock price? Try the links below:Xeris Pharmaceuticals Inc (XERS) Stock Price | Nasdaq
Xeris Pharmaceuticals Inc (XERS) Stock Quote, History and News - Yahoo Finance
Xeris Pharmaceuticals Inc (XERS) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...